Holiday Notification: Cayman Chemical will be closed Monday, May 28, 2012, in observance of the Memorial Day holiday.
More…
Please feel free to continue placing orders via our website or via fax at 734-971-3640. You may send an email to customer service at custserv@caymanchem.com , or to technical support at techserv@caymanchem.com which we will respond to the next business day. Cayman will resume regular business hours and shipping schedules on Tuesday, May 29, 2012. Thank you for your patience and understanding.
Peroxisome proliferator-activated receptors (PPARs) α, δ, γ are ligand-activated nuclear transcription factors involved in the regulation of energy homeostasis as well as insulin sensitivity and glucose metabolism.1,2 Pharmacologies of PPARδ receptor agonists, though relatively obscure, have recently been reported to elevate high-density lipoprotein (HDL) cholesterol and lower plasma triglyceride (TG) levels in obese insulin resistant rhesus monkeys.3 CAY10592 is a full PPARδ agonist (EC50 = 30 nM) in a fatty acid oxidation assay of rat L6 muscle cells with desirable oral pharmacokinetic properties.4 In a transactivation assay using human PPAR receptors, CAY10592 acts as a selective partial PPARδ agonist (EC50 = 53 nM) with no effect on PPARα or PPARγ activity up to 30 µM.4 Chronic treatment of high fat fed ApoB100/CETP-transgenic mice with CAY10592 at a dose of 20 mg/kg increases HDL levels, decreases low-density lipoprotein and TG levels, and improves insulin sensitivity.4
1
Michalik, L., Auwerx, J., Berger, J.P., et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev58726-741(2006).
2
Bratton, L.D., Filzen, G.F., Geyer, A., et al. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) d agonists. Bioorg Med Chem Lett173624-3629(2007).
4
Sauerberg, P., Olsen, G.S., Jeppesen, L., et al. Identification and synthesis of a novel selective partial PPARδ agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem501495-1503(2007).
Sauerberg, P., Olsen, G.S., Jeppesen, L., et al. Identification and synthesis of a novel selective partial PPARδ agonist with full efficacy on lipid metabolism in vitro and in vivo. J Med Chem501495-1503(2007).
Bratton, L.D., Filzen, G.F., Geyer, A., et al. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) d agonists. Bioorg Med Chem Lett173624-3629(2007).
Michalik, L., Auwerx, J., Berger, J.P., et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev58726-741(2006).